| 000 | 00000cam 2200000zi 4500 |
| 001 | 9.960574 |
| 003 | CaOODSP |
| 005 | 20260415114100 |
| 006 | m o d f |
| 007 | cr mn||||||||| |
| 008 | 260304e202604 oncd ob f000 0 eng d |
| 020 | |a9780660987705 |q(statement) |
| 020 | |a9780660987712 |q(summary) |
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
| 043 | |an-cn--- |
| 086 | 1 |aHP40-402/2026E-PDF |
| 086 | 1 |aHP40-402/2026-1E-PDF |
| 245 | 00|aUpdated guidance to protect infants and children from respiratory syncytial virus (RSV) disease : |buse of monoclonal antibodies (nirsevimab and clesrovimab) and the RSVpreF vaccine. |
| 264 | 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cApril 2026. |
| 264 | 4|c©2026 |
| 300 | |a1 online resource (54 pages) + |esummary (5 pages) |
| 336 | |atext|btxt|2rdacontent |
| 337 | |acomputer|bc|2rdamedia |
| 338 | |aonline resource|bcr|2rdacarrier |
| 500 | |aIssued also in French under title: Recommandations mises à jour pour protéger les nourrissons et les enfants contre la maladie causée par le virus respiratoire syncytial (VRS) : utilisation d'anticorps monoclonaux (nirsévimab et clesrovimab) et du vaccin RSVpreF. |
| 500 | |a"An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI)"--Cover. |
| 500 | |a"Pub.: 250479 ." |
| 500 | |a"Pub.: 250481." |
| 500 | |aReplaced with corrected version at the publisher's request (April 15, 2026). |
| 504 | |aIncludes bibliographical references (pages 47-54). |
| 650 | 0|aRespiratory syncytial virus|xVaccination|xGovernment policy|zCanada. |
| 650 | 0|aViral vaccines|xGovernment policy|zCanada. |
| 650 | 0|aVaccination of infants|xGovernment policy|zCanada. |
| 650 | 0|aVaccination of children|xGovernment policy|zCanada. |
| 710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
| 710 | 1 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body. |
| 775 | 08|tRecommandations mises à jour pour protéger les nourrissons et les enfants contre la maladie causée par le virus respiratoire syncytial (VRS) : |w(CaOODSP)9.960580 |
| 856 | 40|qPDF|s1.12 MB|uhttps://publications.gc.ca/collections/collection_2026/aspc-phac/HP40-402-2026-eng.pdf|z(statement) |
| 856 | 40|qPDF|s314 KB|uhttps://publications.gc.ca/collections/collection_2026/aspc-phac/HP40-402-2026-1-eng.pdf|z(summary) |